Akari Therapeutics (AKTX) Expected to Announce Quarterly Earnings on Tuesday

Akari Therapeutics (NASDAQ:AKTX) will likely be releasing its Q4 2025 results after the market closes on Tuesday, April 7th. Analysts expect Akari Therapeutics to post earnings of ($0.0450) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 30, 2026 at 7:00 AM ET.

Akari Therapeutics (NASDAQ:AKTX) last released its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter.

Akari Therapeutics Stock Down 4.2%

Akari Therapeutics stock opened at $0.12 on Tuesday. The business has a 50 day moving average of $0.23 and a 200-day moving average of $0.45. Akari Therapeutics has a 1 year low of $0.12 and a 1 year high of $1.58.

Hedge Funds Weigh In On Akari Therapeutics

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics at the end of the most recent quarter. 5.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

AKTX has been the topic of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, January 21st. LADENBURG THALM/SH SH initiated coverage on shares of Akari Therapeutics in a research note on Monday, January 5th. They set a “buy” rating and a $1.00 price target for the company. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $2.53.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.